Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
May 7, 2026
Angelini Pharma S.p.A. has entered into a definitive agreement to acquire Catalyst Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $4.1 billion. Angelini will pay $31.50 per share and the deal is expected to close in the third quarter of 2026, subject to regulatory approvals and Catalyst stockholder approval.
- Buyers
- Angelini Pharma S.p.A., Blackstone funds, CDP Equity, BNP Paribas
- Targets
- Catalyst Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Florida, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.